EPA:HRMS.PA News 24 January 2026

January 24, 2026, 7:19 PM EST. Stryker's shares slipped 9.1% over the past year but show strong gains of 43.8% over three years and 69.1% over five years. The medical technology firm's stock closed at $355.04, prompting debate on whether it prices in too much optimism. A Discounted Cash Flow (DCF) analysis estimates intrinsic value at $298.65 per share, suggesting the stock trades at an 18.9% premium and is overvalued on this metric. Other valuation checks yield mixed signals, with Stryker scoring 1 out of 6 indicating undervaluation in only one measure. Investors continue to balance its long-term healthcare role against current pricing, contributing to short-term weakness amid solid multi-year returns. The mixed valuation results highlight ongoing uncertainty about the stock's fair value amid evolving growth prospects and risk assessments.